-
Aurigene
Aurigene Discovery Technologies Limited, India is a Drug Discovery Biotech engaged in small molecule and peptide drug discovery.
With comprehensive capabilities spanning target validation and hit generation to IND filing, Aurigene has 2 sites located in Bangalore (over 200,000 sft) and Hyderabad (over 100,000 sft) and over 425 scientific staff.
Aurigene’s key businesses are Collaborative Drug Discovery partnerships, Licensing and Drug Discovery services.
Aurigene currently runs over 20 Discovery programs with 9 collaborators world-wide, spanning Big Pharma as well as successful Biotech’s.
Aurigene’s core technology strengths are in Structural Biology including SBDD and Fragment-based Hit/ Lead generation.
Therapeutic areas of focus include Oncology, Inflammation (OA, RA), Metabolic Disorders, Anti-infectives and Pain.
|
News
01-Sep-2009
Aurigene Announces Completion of Purchase of Discovery Research Facility in Hyderabad 03-Feb-2009 Aurigene Announce Significant Milestone in a Collaboration Program 24-Nov-2008 Aurigene in licensing agreement with Debiopharm 25-Jun-2008 Aurigene Achieves 2nd Milestone in Second Discovery Partnership With MerckSerono 25-Apr-2007 Orion and Aurigene to Collaborate on First in Class Drugs for Cancer Treatment 02-Feb-2007 Discovery Collaborations with Forest Labs on Obesity targets 28-Jun-2006 Agreement with Debiopharm on Immuno oncology targets |
|
Events
05-Sep-2010 to 09-Sep-2010
ISMC 2010,Brussels, Belgium Click here to view more details 14-Sep-2010 to 16-Sep-2010 ChemOutsourcing,Long Branch, NJ, USA Click here to view more details 15-Sep-2010 to 17-Sep-2010 BioPharm America,Boston, MA , USA Click here to view more details 21-Sep-2010 to 22-Sep-2010 BIO Asia,Hyderabad, India Click here to view more details 15-Nov-2010 to 17-Nov-2010 BIO-Europe 2010,Munich, Germany Click here to view more details |
|
Testimonials
“We started our first collaboration project with Aurigene early 2007. The collaboration has been such a success that we have started new projects alongside the first one. We increased the collaboration because we have learned about the impressive technological and research capabilities within the relevant areas of drug discovery, which was also seen in the productivity. Especially happy I am about the open professional atmosphere between the scientists in both companies with commitment to the common goals. Synergistic collaboration and flexibility in the business model of Aurigene is really working, TPP can be modified along the project in the light of new information.” - Dr. Antti Haapalinna, Vice President Research, Orion Pharma
"Working with Aurigene has been a real pleasure. They have proven to be efficacious on the business side and fully committed to meeting their goals in a timely manner. This in an atmosphere of high quality scientific work" - Dr. Andres McAllister, Chief Scientific Officer, Debiopharm S.A “Aurigene has been an excellent company to work with. Their scientific team is highly productive, responsive and quite knowledgeable, allowing Aurigene to execute even the most challenging projects in a timely manner. Their team communicates and interacts effectively with our scientists and project managers. Aurigene’s success in carrying out our projects is due not only to their excellent team of scientists, but also to their strong infrastructure, state-of-the-art equipment and dedicated professionals in project management, procurement and logistics” - Dr. M. Bhupathy, Executive Director, Amgen Inc. |